RT Journal Article
SR Electronic
T1 Surface and air contamination with SARS-CoV-2 from hospitalized COVID-19 patients in Toronto, Canada
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.17.21257122
DO 10.1101/2021.05.17.21257122
A1 Jonathon D. Kotwa
A1 Alainna J. Jamal
A1 Hamza Mbareche
A1 Lily Yip
A1 Patryk Aftanas
A1 Shiva Barati
A1 Natalie G. Bell
A1 Elizabeth Bryce
A1 Eric Coomes
A1 Gloria Crowl
A1 Caroline Duchaine
A1 Amna Faheem
A1 Lubna Farooqi
A1 Ryan Hiebert
A1 Kevin Katz
A1 Saman Khan
A1 Robert Kozak
A1 Angel X. Li
A1 Henna P. Mistry
A1 Mohammad Mozafarihashjin
A1 Jalees A. Nasir
A1 Kuganya Nirmalarajah
A1 Emily M. Panousis
A1 Aimee Paterson
A1 Simon Plenderleith
A1 Jeff Powis
A1 Karren Prost
A1 Renée Schryer
A1 Maureen Taylor
A1 Marc Veillette
A1 Titus Wong
A1 Xi Zoe Zhong
A1 Andrew G. McArthur
A1 Allison J. McGeer
A1 Samira Mubareka
YR 2021
UL http://medrxiv.org/content/early/2021/05/20/2021.05.17.21257122.abstract
AB Background The aim of this prospective cohort study was to determine the burden of SARS-CoV-2 in air and on surfaces in rooms of patients hospitalized with COVID-19, and to identify patient characteristics associated with SARS-CoV-2 environmental contamination.Methods Nasopharyngeal swabs, surface, and air samples were collected from the rooms of 78 inpatients with COVID-19 at six acute care hospitals in Toronto from March to May 2020. Samples were tested for SARS-CoV-2 viral RNA and cultured to determine potential infectivity. Whole viral genomes were sequenced from nasopharyngeal and surface samples. Association between patient factors and detection of SARS-CoV-2 RNA in surface samples were investigated using a mixed-effects logistic regression model.Findings SARS-CoV-2 RNA was detected from surfaces (125/474 samples; 42/78 patients) and air (3/146 samples; 3/45 patients) in COVID-19 patient rooms; 14% (6/42) of surface samples from three patients yielded viable virus. Viral sequences from nasopharyngeal and surface samples clustered by patient.Multivariable analysis indicated hypoxia at admission, a PCR-positive nasopharyngeal swab with a cycle threshold of ≤30 on or after surface sampling date, higher Charlson co-morbidity score, and shorter time from onset of illness to sample date were significantly associated with detection of SARS-CoV-2 RNA in surface samples.Interpretation The infrequent recovery of infectious SARS-CoV-2 virus from the environment suggests that the risk to healthcare workers from air and near-patient surfaces in acute care hospital wards is likely limited. Surface contamination was greater when patients were earlier in their course of illness and in those with hypoxia, multiple co-morbidities, and higher SARS-CoV-2 RNA concentration in NP swabs. Our results suggest that air and surfaces may pose limited risk a few days after admission to acute care hospitals.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Canadian Institutes of Health Research (CIHR No. RN419944-439999) as well as Genome Canada CanCOGeN funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research ethics approval was granted by all participating The Toronto Invasive Bacterial Diseases Network hospitals (Sunnybrooks Research Ethics Board, The Mount Sinai Hospital Research Ethics Board, Toronto East Health Network Research Ethics Board, Oslers Research Ethics Board, and Scarborough Health Networks Research Ethics Board).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, SM, upon reasonable request.